<?xml version="1.0" encoding="UTF-8"?>
<drug type="small molecule" created="2007-07-24" updated="2020-01-02">
  <drugbank-id primary="true">DB01432</drugbank-id>
  <name>Cholestyramine</name>
  <description>Cholestyramine or colestyramine is a bile acid sequestrant. Bile acid sequestrants are polymeric compounds which serve as ion exchange resins. Cholestyramine resin is quite hydrophilic, but insoluble in water.</description>
  <cas-number>11041-12-6</cas-number>
  <unii>4B33BGI082</unii>
  <state>solid</state>
  <groups>
    <group>approved</group>
    <group>investigational</group>
  </groups>
  <general-references>
    <articles/>
    <textbooks/>
    <links/>
    <attachments/>
  </general-references>
  <synthesis-reference>Moh. S. Amer, Jack C. Gray, "Cholestyramine compositions and method for preparation thereof." U.S. Patent US4895723, issued March, 1967.</synthesis-reference>
  <indication>Indicated as adjunctive therapy to diet for the reduction of elevated serum cholesterol in patients with primary hypercholesterolemia (elevated low density lipoprotein [LDL] cholesterol) who do not respond adequately to diet. Also for the relief of pruritus associated with partial biliary obstruction.</indication>
  <pharmacodynamics>Cholesterol is probably the sole precursor of bile acids. During normal digestion, bile acids are secreted into the intestines. A major portion of the bile acids is absorbed from the intestinal tract and returned to the liver via the enterohepatic circulation. Only very small amounts of bile acids are found in normal serum. Cholestyramine resin adsorbs and combines with the bile acids in the intestine to form an insoluble complex which is excreted in the feces. This results in a partial removal of bile acids from the enterohepatic circulation by preventing their absorption.</pharmacodynamics>
  <mechanism-of-action>Cholestyramine forms a resin that acts as a bile acid sequestrant to limit the reabsorption of bile acids in the gastrointestinal tract. Cholestyramine resin is a strong anion exchange resin, allowing it to exchange its chloride anions with anionic bile acids present in the gastrointestinal tract and form a strong resin matrix. Cholestyramine consists of a functional group, which is a quaternary ammonium group attached to an inert styrene-divinylbenzene copolymer, in the anion exchange resin.</mechanism-of-action>
  <toxicity>Overdose may result in blockage of intestine or stomach.</toxicity>
  <metabolism>Bile acids</metabolism>
  <absorption>Not absorbed from the gastrointestinal tract following oral administration.</absorption>
  <half-life>6 minutes</half-life>
  <protein-binding/>
  <route-of-elimination>Cholestyramine resin adsorbs and combines with the bile acids in the intestine to form an insoluble complex which is excreted in the feces.</route-of-elimination>
  <volume-of-distribution/>
  <clearance/>
  <salts/>
  <synonyms>
    <synonym language="english" coder="">Cholestyramine resin</synonym>
    <synonym language="spanish" coder="">Colestiramina</synonym>
    <synonym language="english" coder="">Colestyramine</synonym>
  </synonyms>
  <products>
    <product>
      <name>Alti-cholestyramine Light</name>
      <labeller>Altimed Pharma Inc.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02054825</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1994-12-31</started-marketing-on>
      <ended-marketing-on>1999-09-17</ended-marketing-on>
      <dosage-form>Kit; Powder</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Cholestyramine</name>
      <labeller>Physicians Total Care, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>54868-4812</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2010-03-22</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Powder, for suspension</dosage-form>
      <strength>4 g/9g</strength>
      <route>Oral</route>
      <fda-application-number>ANDA077204</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Cholestyramine</name>
      <labeller>Physicians Total Care, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>54868-5526</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2006-02-08</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Powder, for suspension</dosage-form>
      <strength>4 g/5g</strength>
      <route>Oral</route>
      <fda-application-number>ANDA077203</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Cholestyramine</name>
      <labeller>Golden State Medical Supply</labeller>
      <ndc-id/>
      <ndc-product-code>60429-355</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2005-09-15</started-marketing-on>
      <ended-marketing-on>2017-01-02</ended-marketing-on>
      <dosage-form>Powder, for suspension</dosage-form>
      <strength>4 g/9g</strength>
      <route>Oral</route>
      <fda-application-number>ANDA077203</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Cholestyramine</name>
      <labeller>Eon Labs, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>0185-0940</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1996-08-15</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Powder, for suspension</dosage-form>
      <strength>4 g/9g</strength>
      <route>Oral</route>
      <fda-application-number>ANDA074557</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Cholestyramine</name>
      <labeller>Upsher Smith Laboratories</labeller>
      <ndc-id/>
      <ndc-product-code>0245-0536</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1996-08-15</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Powder, for suspension</dosage-form>
      <strength>4 g/9g</strength>
      <route>Oral</route>
      <fda-application-number>ANDA074557</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Cholestyramine</name>
      <labeller>A-S Medication Solutions</labeller>
      <ndc-id/>
      <ndc-product-code>50090-3845</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2017-06-08</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Powder, for suspension</dosage-form>
      <strength>4 g/5.5g</strength>
      <route>Oral</route>
      <fda-application-number>ANDA202902</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Cholestyramine</name>
      <labeller>Cadila Healthcare Limited</labeller>
      <ndc-id/>
      <ndc-product-code>70771-1105</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2018-08-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Powder, for suspension</dosage-form>
      <strength>4 g/9g</strength>
      <route>Oral</route>
      <fda-application-number>ANDA202901</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Cholestyramine</name>
      <labeller>Zydus Pharmaceuticals (USA) Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>68382-528</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2018-08-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Powder, for suspension</dosage-form>
      <strength>4 g/9g</strength>
      <route>Oral</route>
      <fda-application-number>ANDA202901</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Cholestyramine</name>
      <labeller>Zydus Pharmaceuticals (USA) Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>68382-529</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2017-06-08</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Powder, for suspension</dosage-form>
      <strength>4 g/5.5g</strength>
      <route>Oral</route>
      <fda-application-number>ANDA202902</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Cholestyramine</name>
      <labeller>ANI Pharmaceuticals, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>62559-620</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2018-06-26</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Powder, for suspension</dosage-form>
      <strength>4 g/9g</strength>
      <route>Oral</route>
      <fda-application-number>ANDA074554</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Cholestyramine</name>
      <labeller>Par Pharmaceutical, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>49884-465</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2005-09-15</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Powder, for suspension</dosage-form>
      <strength>4 g/9g</strength>
      <route>Oral</route>
      <fda-application-number>ANDA077204</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Cholestyramine</name>
      <labeller>Par Pharmaceutical, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>49884-466</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2005-09-15</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Powder, for suspension</dosage-form>
      <strength>4 g/5g</strength>
      <route>Oral</route>
      <fda-application-number>ANDA077203</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Cholestyramine</name>
      <labeller>Cadila Healthcare Limited</labeller>
      <ndc-id/>
      <ndc-product-code>70771-1070</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2017-06-08</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Powder, for suspension</dosage-form>
      <strength>4 g/5.5g</strength>
      <route>Oral</route>
      <fda-application-number>ANDA202902</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Cholestyramine</name>
      <labeller>Sorres Pharma Inc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02236969</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1998-02-17</started-marketing-on>
      <ended-marketing-on>2010-10-19</ended-marketing-on>
      <dosage-form>Powder, for suspension</dosage-form>
      <strength>4 g</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Cholestyramine</name>
      <labeller>Sorres Pharma Inc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02236970</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1998-02-17</started-marketing-on>
      <ended-marketing-on>2010-10-06</ended-marketing-on>
      <dosage-form>Powder, for suspension</dosage-form>
      <strength>4 g</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Cholestyramine Cholestyramine Resin</name>
      <labeller>Nanjing Lifecare Pharmaceutical Co. Ltd.</labeller>
      <ndc-id/>
      <ndc-product-code>26692-0419</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2011-05-30</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Powder</dosage-form>
      <strength>1 kg/1kg</strength>
      <route>Not applicable</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Cholestyramine Light</name>
      <labeller>Golden State Medical Supply</labeller>
      <ndc-id/>
      <ndc-product-code>60429-356</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2005-09-15</started-marketing-on>
      <ended-marketing-on>2017-01-02</ended-marketing-on>
      <dosage-form>Powder, for suspension</dosage-form>
      <strength>4 g/5g</strength>
      <route>Oral</route>
      <fda-application-number>ANDA077204</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Cholestyramine Light</name>
      <labeller>Eon Labs, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>0185-0939</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1994-11-04</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Powder, for suspension</dosage-form>
      <strength>4 g/5.7g</strength>
      <route>Oral</route>
      <fda-application-number>ANDA074558</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Cholestyramine-odan</name>
      <labeller>Odan Laboratories Ltd</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02455609</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2016-12-23</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Powder, for suspension</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Jamp-cholestyramine</name>
      <labeller>Jamp Pharma Corporation</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02478595</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on/>
      <ended-marketing-on/>
      <dosage-form>Powder, for suspension</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Jamp-cholestyramine</name>
      <labeller>Jamp Pharma Corporation</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02494531</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on/>
      <ended-marketing-on/>
      <dosage-form>Powder, for suspension</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Novo-cholamine - Pwr 4g/dose</name>
      <labeller>Novopharm Limited</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02139189</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1995-12-31</started-marketing-on>
      <ended-marketing-on>2015-10-26</ended-marketing-on>
      <dosage-form>Powder; Suspension</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Novo-cholamine Light - Pwr 4g/dose</name>
      <labeller>Novopharm Limited</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02139197</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1995-12-31</started-marketing-on>
      <ended-marketing-on>2015-10-26</ended-marketing-on>
      <dosage-form>Powder; Suspension</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Olestyr</name>
      <labeller>Pharmascience Inc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>00890960</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1993-12-31</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Powder, for suspension</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Olestyr</name>
      <labeller>Pharmascience Inc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02210320</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1996-03-15</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Powder, for suspension</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>PHL-cholestyramine Light - 210g Tin</name>
      <labeller>Pharmel Inc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02237132</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1998-02-17</started-marketing-on>
      <ended-marketing-on>2010-10-06</ended-marketing-on>
      <dosage-form>Powder, for suspension</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>PHL-cholestyramine Powder 210g/can</name>
      <labeller>Pharmel Inc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02259249</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2004-12-06</started-marketing-on>
      <ended-marketing-on>2010-10-06</ended-marketing-on>
      <dosage-form>Powder, for suspension</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>PHL-cholestyramine Powder for Suspension 400gm/can</name>
      <labeller>Pharmel Inc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02259257</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2004-12-06</started-marketing-on>
      <ended-marketing-on>2010-10-06</ended-marketing-on>
      <dosage-form>Powder, for suspension</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>PHL-cholestyramine Regular - 378g Tin</name>
      <labeller>Pharmel Inc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02237133</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1998-02-17</started-marketing-on>
      <ended-marketing-on>2010-10-06</ended-marketing-on>
      <dosage-form>Powder, for suspension</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>PMS-cholestyramine</name>
      <labeller>Pharmascience Inc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02458365</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on/>
      <ended-marketing-on/>
      <dosage-form>Powder, for suspension</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>PMS-cholestyramine</name>
      <labeller>Pharmascience Inc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02458373</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on/>
      <ended-marketing-on/>
      <dosage-form>Powder, for suspension</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>PMS-cholestyramine Powder 210g/can</name>
      <labeller>Pharmascience Inc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02141795</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1995-12-31</started-marketing-on>
      <ended-marketing-on>2007-06-19</ended-marketing-on>
      <dosage-form>Powder, for solution</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>PMS-cholestyramine Pws 400g/can</name>
      <labeller>Pharmascience Inc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02125463</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1995-12-31</started-marketing-on>
      <ended-marketing-on>2010-08-11</ended-marketing-on>
      <dosage-form>Powder, for solution</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>PMS-cholestyramine Regular Powder -4/9g Dose</name>
      <labeller>Pharmascience Inc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02207745</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1996-12-31</started-marketing-on>
      <ended-marketing-on>2010-08-11</ended-marketing-on>
      <dosage-form>Powder</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Prevalite</name>
      <labeller>Upsher-Smith Laboratories, LLC</labeller>
      <ndc-id/>
      <ndc-product-code>0245-0036</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1996-02-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Powder, for suspension</dosage-form>
      <strength>4 g/5.5g</strength>
      <route>Oral</route>
      <fda-application-number>ANDA073263</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Questran</name>
      <labeller>Par Pharmaceutical</labeller>
      <ndc-id/>
      <ndc-product-code>49884-791</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2009-06-01</started-marketing-on>
      <ended-marketing-on>2011-09-09</ended-marketing-on>
      <dosage-form>Powder, for suspension</dosage-form>
      <strength>4 g/9g</strength>
      <route>Oral</route>
      <fda-application-number>NDA016640</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Questran</name>
      <labeller>Par Pharmaceutical</labeller>
      <ndc-id/>
      <ndc-product-code>49884-792</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2009-06-01</started-marketing-on>
      <ended-marketing-on>2011-09-09</ended-marketing-on>
      <dosage-form>Powder, for suspension</dosage-form>
      <strength>4 g/6.4g</strength>
      <route>Oral</route>
      <fda-application-number>NDA019669</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Questran</name>
      <labeller>Physicians Total Care, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>54868-2647</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2005-09-15</started-marketing-on>
      <ended-marketing-on>2010-06-30</ended-marketing-on>
      <dosage-form>Powder, for suspension</dosage-form>
      <strength>4 g/5g</strength>
      <route>Oral</route>
      <fda-application-number>ANDA077203</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Questran</name>
      <labeller>Par Pharmaceutical, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>49884-936</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2005-09-15</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Powder, for suspension</dosage-form>
      <strength>4 g/9g</strength>
      <route>Oral</route>
      <fda-application-number>ANDA077204</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Questran</name>
      <labeller>Par Pharmaceutical, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>49884-937</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2003-07-24</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Powder, for suspension</dosage-form>
      <strength>4 g/5g</strength>
      <route>Oral</route>
      <fda-application-number>ANDA077203</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Questran Light Pws 4gm/pck</name>
      <labeller>Bristol Labs Division Of Bristol Myers Squibb</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>01918486</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1991-12-31</started-marketing-on>
      <ended-marketing-on>2005-08-01</ended-marketing-on>
      <dosage-form>Powder, for solution</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Questran Pwr 378gm/can</name>
      <labeller>Bristol Labs Division Of Bristol Myers Squibb</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>00634093</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1985-12-31</started-marketing-on>
      <ended-marketing-on>2005-08-01</ended-marketing-on>
      <dosage-form>Powder, for solution</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Questran Pwr 4gm/9gm</name>
      <labeller>Bristol Labs Division Of Bristol Myers Squibb</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>00464880</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1979-12-31</started-marketing-on>
      <ended-marketing-on>2005-08-01</ended-marketing-on>
      <dosage-form>Powder, for solution</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Questran Tab 1gm</name>
      <labeller>Bristol Myers Squibb</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>01966014</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1993-12-31</started-marketing-on>
      <ended-marketing-on>1999-08-09</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
  </products>
  <international-brands>
    <international-brand>
      <name>Cholybar</name>
      <company/>
    </international-brand>
    <international-brand>
      <name>Locholest</name>
      <company/>
    </international-brand>
    <international-brand>
      <name>Locholest light</name>
      <company/>
    </international-brand>
    <international-brand>
      <name>Questran Light</name>
      <company/>
    </international-brand>
  </international-brands>
  <mixtures>
    <mixture>
      <name>Cholestyramine</name>
      <ingredients>Cholestyramine</ingredients>
    </mixture>
    <mixture>
      <name>Cholestyramine</name>
      <ingredients>Cholestyramine</ingredients>
    </mixture>
    <mixture>
      <name>Questran</name>
      <ingredients>Cholestyramine</ingredients>
    </mixture>
    <mixture>
      <name>Questran</name>
      <ingredients>Cholestyramine</ingredients>
    </mixture>
    <mixture>
      <name>Questran</name>
      <ingredients>Cholestyramine</ingredients>
    </mixture>
    <mixture>
      <name>Cholestyramine</name>
      <ingredients>Cholestyramine</ingredients>
    </mixture>
    <mixture>
      <name>Cholestyramine Light</name>
      <ingredients>Cholestyramine</ingredients>
    </mixture>
    <mixture>
      <name>Cholestyramine</name>
      <ingredients>Cholestyramine</ingredients>
    </mixture>
    <mixture>
      <name>Cholestyramine Light</name>
      <ingredients>Cholestyramine</ingredients>
    </mixture>
    <mixture>
      <name>Cholestyramine</name>
      <ingredients>Cholestyramine</ingredients>
    </mixture>
    <mixture>
      <name>Cholestyramine</name>
      <ingredients>Cholestyramine</ingredients>
    </mixture>
    <mixture>
      <name>Prevalite</name>
      <ingredients>Cholestyramine</ingredients>
    </mixture>
    <mixture>
      <name>Cholestyramine Cholestyramine Resin</name>
      <ingredients>Cholestyramine</ingredients>
    </mixture>
    <mixture>
      <name>Cholestyramine</name>
      <ingredients>Cholestyramine</ingredients>
    </mixture>
    <mixture>
      <name>Cholestyramine</name>
      <ingredients>Cholestyramine</ingredients>
    </mixture>
    <mixture>
      <name>Cholestyramine</name>
      <ingredients>Cholestyramine</ingredients>
    </mixture>
    <mixture>
      <name>Cholestyramine</name>
      <ingredients>Cholestyramine</ingredients>
    </mixture>
    <mixture>
      <name>Questran</name>
      <ingredients>Cholestyramine</ingredients>
    </mixture>
    <mixture>
      <name>Questran</name>
      <ingredients>Cholestyramine</ingredients>
    </mixture>
    <mixture>
      <name>Cholestyramine</name>
      <ingredients>Cholestyramine</ingredients>
    </mixture>
    <mixture>
      <name>Cholestyramine</name>
      <ingredients>Cholestyramine</ingredients>
    </mixture>
    <mixture>
      <name>Cholestyramine</name>
      <ingredients>Cholestyramine</ingredients>
    </mixture>
    <mixture>
      <name>Questran Light Pws 4gm/pck</name>
      <ingredients>Cholestyramine</ingredients>
    </mixture>
    <mixture>
      <name>Questran Tab 1gm</name>
      <ingredients>Cholestyramine</ingredients>
    </mixture>
    <mixture>
      <name>Alti-cholestyramine Light</name>
      <ingredients>Cholestyramine</ingredients>
    </mixture>
    <mixture>
      <name>PMS-cholestyramine Powder 210g/can</name>
      <ingredients>Cholestyramine</ingredients>
    </mixture>
    <mixture>
      <name>PMS-cholestyramine Pws 400g/can</name>
      <ingredients>Cholestyramine</ingredients>
    </mixture>
    <mixture>
      <name>PMS-cholestyramine Regular Powder -4/9g Dose</name>
      <ingredients>Cholestyramine</ingredients>
    </mixture>
    <mixture>
      <name>Questran Pwr 4gm/9gm</name>
      <ingredients>Cholestyramine</ingredients>
    </mixture>
    <mixture>
      <name>Cholestyramine</name>
      <ingredients>Cholestyramine</ingredients>
    </mixture>
    <mixture>
      <name>Cholestyramine</name>
      <ingredients>Cholestyramine</ingredients>
    </mixture>
    <mixture>
      <name>PHL-cholestyramine Light - 210g Tin</name>
      <ingredients>Cholestyramine</ingredients>
    </mixture>
    <mixture>
      <name>PHL-cholestyramine Regular - 378g Tin</name>
      <ingredients>Cholestyramine</ingredients>
    </mixture>
    <mixture>
      <name>Questran Pwr 378gm/can</name>
      <ingredients>Cholestyramine</ingredients>
    </mixture>
    <mixture>
      <name>PHL-cholestyramine Powder 210g/can</name>
      <ingredients>Cholestyramine</ingredients>
    </mixture>
    <mixture>
      <name>PHL-cholestyramine Powder for Suspension 400gm/can</name>
      <ingredients>Cholestyramine</ingredients>
    </mixture>
    <mixture>
      <name>Novo-cholamine Light - Pwr 4g/dose</name>
      <ingredients>Cholestyramine</ingredients>
    </mixture>
    <mixture>
      <name>Novo-cholamine - Pwr 4g/dose</name>
      <ingredients>Cholestyramine</ingredients>
    </mixture>
    <mixture>
      <name>PMS-cholestyramine</name>
      <ingredients>Cholestyramine</ingredients>
    </mixture>
    <mixture>
      <name>PMS-cholestyramine</name>
      <ingredients>Cholestyramine</ingredients>
    </mixture>
    <mixture>
      <name>Cholestyramine-odan</name>
      <ingredients>Cholestyramine</ingredients>
    </mixture>
    <mixture>
      <name>Olestyr</name>
      <ingredients>Cholestyramine</ingredients>
    </mixture>
    <mixture>
      <name>Olestyr</name>
      <ingredients>Cholestyramine</ingredients>
    </mixture>
    <mixture>
      <name>Jamp-cholestyramine</name>
      <ingredients>Cholestyramine</ingredients>
    </mixture>
    <mixture>
      <name>Jamp-cholestyramine</name>
      <ingredients>Cholestyramine</ingredients>
    </mixture>
  </mixtures>
  <packagers>
    <packager>
      <name>A-S Medication Solutions LLC</name>
      <url>http://orders.a-smeds.com</url>
    </packager>
    <packager>
      <name>Bristol-Myers Squibb Co.</name>
      <url>http://www.bms.com</url>
    </packager>
    <packager>
      <name>Catalent Pharma Solutions</name>
      <url>http://www.catalent.com</url>
    </packager>
    <packager>
      <name>Eon Labs</name>
      <url/>
    </packager>
    <packager>
      <name>Major Pharmaceuticals</name>
      <url>http://www.majorpharmaceuticals.com</url>
    </packager>
    <packager>
      <name>Mead Johnson and Co.</name>
      <url>http://www.meadjohnson.com</url>
    </packager>
    <packager>
      <name>Medisca Inc.</name>
      <url>http://www.medisca.com</url>
    </packager>
    <packager>
      <name>Novopharm Ltd.</name>
      <url/>
    </packager>
    <packager>
      <name>Par Pharmaceuticals</name>
      <url>http://www.parpharm.com</url>
    </packager>
    <packager>
      <name>Physicians Total Care Inc.</name>
      <url>http://www.physicianstotalcare.com</url>
    </packager>
    <packager>
      <name>Upsher Smith Laboratories</name>
      <url>http://www.upsher-smith.com</url>
    </packager>
  </packagers>
  <manufacturers/>
  <prices>
    <price>
      <description>Pms-Cholestyramine Light 4 g Powder Packet</description>
      <cost currency="USD">1.41</cost>
      <unit>packet</unit>
    </price>
    <price>
      <description>Pms-Cholestyramine Regular 4 g Powder Packet</description>
      <cost currency="USD">1.41</cost>
      <unit>packet</unit>
    </price>
    <price>
      <description>Prevalite packet</description>
      <cost currency="USD">2.58</cost>
      <unit>each</unit>
    </price>
    <price>
      <description>Cholestyramine light packet</description>
      <cost currency="USD">3.35</cost>
      <unit>each</unit>
    </price>
    <price>
      <description>Cholestyramine Light 4 gm Packets</description>
      <cost currency="USD">3.49</cost>
      <unit>packet</unit>
    </price>
    <price>
      <description>Cholestyramine 4 gm Packets</description>
      <cost currency="USD">3.5</cost>
      <unit>packet</unit>
    </price>
    <price>
      <description>Questran packet</description>
      <cost currency="USD">4.23</cost>
      <unit>each</unit>
    </price>
    <price>
      <description>Questran light packet</description>
      <cost currency="USD">4.25</cost>
      <unit>each</unit>
    </price>
    <price>
      <description>Questran 4 gm Packets</description>
      <cost currency="USD">4.4</cost>
      <unit>packet</unit>
    </price>
    <price>
      <description>Cholestyramine resin powder</description>
      <cost currency="USD">16.83</cost>
      <unit>g</unit>
    </price>
    <price>
      <description>Cholestyramine 4 gm/dose Powder 378 gm Can</description>
      <cost currency="USD">57.99</cost>
      <unit>can</unit>
    </price>
    <price>
      <description>Cholestyramine Light 4 gm/dose Powder 210 gm Can</description>
      <cost currency="USD">57.99</cost>
      <unit>can</unit>
    </price>
    <price>
      <description>Questran Light 4 gm/dose Powder 268 gm Can</description>
      <cost currency="USD">102.35</cost>
      <unit>can</unit>
    </price>
    <price>
      <description>Questran 4 gm/dose Powder 378 gm Can</description>
      <cost currency="USD">115.62</cost>
      <unit>can</unit>
    </price>
    <price>
      <description>Questran Light 4 gm/dose Powder 210 gm Can</description>
      <cost currency="USD">116.3</cost>
      <unit>can</unit>
    </price>
  </prices>
  <categories>
    <category>
      <category>Anion Exchange Resins</category>
      <mesh-id>D000837</mesh-id>
    </category>
    <category>
      <category>Anticholesteremic Agents</category>
      <mesh-id>D000924</mesh-id>
    </category>
    <category>
      <category>Benzene Derivatives</category>
      <mesh-id>D001555</mesh-id>
    </category>
    <category>
      <category>Benzylidene Compounds</category>
      <mesh-id>D001597</mesh-id>
    </category>
    <category>
      <category>Bile Acid Sequestrants</category>
      <mesh-id/>
    </category>
    <category>
      <category>Bile-acid Binding Activity</category>
      <mesh-id/>
    </category>
    <category>
      <category>Compounds used in a research, industrial, or household setting</category>
      <mesh-id>D020313</mesh-id>
    </category>
    <category>
      <category>Hypolipidemic Agents</category>
      <mesh-id>D000960</mesh-id>
    </category>
    <category>
      <category>Ion Exchange Resins</category>
      <mesh-id>D007475</mesh-id>
    </category>
    <category>
      <category>Laboratory Chemicals</category>
      <mesh-id>D019995</mesh-id>
    </category>
    <category>
      <category>Lipid Modifying Agents</category>
      <mesh-id/>
    </category>
    <category>
      <category>Lipid Modifying Agents, Plain</category>
      <mesh-id/>
    </category>
    <category>
      <category>Lipid Regulating Agents</category>
      <mesh-id>D057847</mesh-id>
    </category>
    <category>
      <category>Macromolecular Substances</category>
      <mesh-id>D046911</mesh-id>
    </category>
    <category>
      <category>Noxae</category>
      <mesh-id>D009676</mesh-id>
    </category>
    <category>
      <category>Plastics</category>
      <mesh-id>D010969</mesh-id>
    </category>
    <category>
      <category>Polymers</category>
      <mesh-id>D011108</mesh-id>
    </category>
    <category>
      <category>Polystyrenes</category>
      <mesh-id>D011137</mesh-id>
    </category>
    <category>
      <category>Styrene</category>
      <mesh-id>D020058</mesh-id>
    </category>
    <category>
      <category>Styrenes</category>
      <mesh-id>D013343</mesh-id>
    </category>
    <category>
      <category>Toxic Actions</category>
      <mesh-id>D004786</mesh-id>
    </category>
  </categories>
  <affected-organisms>
    <affected-organism>Humans and other mammals</affected-organism>
  </affected-organisms>
  <dosages>
    <dosage>
      <form>Kit; powder</form>
      <route>Oral</route>
      <strength/>
    </dosage>
    <dosage>
      <form>Powder, for suspension</form>
      <route>Oral</route>
      <strength>4 g/9g</strength>
    </dosage>
    <dosage>
      <form>Powder, for suspension</form>
      <route>Oral</route>
      <strength>4 g/5g</strength>
    </dosage>
    <dosage>
      <form>Powder, for suspension</form>
      <route>Oral</route>
      <strength>4 g</strength>
    </dosage>
    <dosage>
      <form>Powder, for suspension</form>
      <route>Oral</route>
      <strength>4 g/5.5g</strength>
    </dosage>
    <dosage>
      <form>Powder</form>
      <route>Not applicable</route>
      <strength>1 kg/1kg</strength>
    </dosage>
    <dosage>
      <form>Powder, for suspension</form>
      <route>Oral</route>
      <strength>4 g/5.7g</strength>
    </dosage>
    <dosage>
      <form>Powder; suspension</form>
      <route>Oral</route>
      <strength/>
    </dosage>
    <dosage>
      <form>Powder, for suspension</form>
      <route>Oral</route>
      <strength/>
    </dosage>
    <dosage>
      <form>Powder</form>
      <route>Oral</route>
      <strength/>
    </dosage>
    <dosage>
      <form>Powder, for suspension</form>
      <route>Oral</route>
      <strength>4 g/6.4g</strength>
    </dosage>
    <dosage>
      <form>Powder, for solution</form>
      <route>Oral</route>
      <strength/>
    </dosage>
    <dosage>
      <form>Tablet</form>
      <route>Oral</route>
      <strength/>
    </dosage>
  </dosages>
  <atc-codes>
    <atc-code code="C10AC01">
      <level code="C10AC">Bile acid sequestrants</level>
      <level code="C10A">LIPID MODIFYING AGENTS, PLAIN</level>
      <level code="C10">LIPID MODIFYING AGENTS</level>
      <level code="C">CARDIOVASCULAR SYSTEM</level>
    </atc-code>
  </atc-codes>
  <ahfs-codes>
    <ahfs-code>24:06.04</ahfs-code>
  </ahfs-codes>
  <pdb-entries/>
  <msds>//s3-us-west-2.amazonaws.com/drugbank/msds/DB01432.pdf?1265922745</msds>
  <patents/>
  <food-interactions>
    <food-interaction>Take with food, do not mix with soft drinks.</food-interaction>
  </food-interactions>
  <drug-interactions>
    <drug-interaction>
      <drugbank-id>DB01118</drugbank-id>
      <name>Amiodarone</name>
      <description>The excretion of Amiodarone can be increased when combined with Cholestyramine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00175</drugbank-id>
      <name>Pravastatin</name>
      <description>Cholestyramine can cause a decrease in the absorption of Pravastatin resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00227</drugbank-id>
      <name>Lovastatin</name>
      <description>Cholestyramine can cause a decrease in the absorption of Lovastatin resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00439</drugbank-id>
      <name>Cerivastatin</name>
      <description>Cholestyramine can cause a decrease in the absorption of Cerivastatin resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00641</drugbank-id>
      <name>Simvastatin</name>
      <description>Cholestyramine can cause a decrease in the absorption of Simvastatin resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01076</drugbank-id>
      <name>Atorvastatin</name>
      <description>Cholestyramine can cause a decrease in the absorption of Atorvastatin resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01098</drugbank-id>
      <name>Rosuvastatin</name>
      <description>Cholestyramine can cause a decrease in the absorption of Rosuvastatin resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06693</drugbank-id>
      <name>Mevastatin</name>
      <description>Cholestyramine can cause a decrease in the absorption of Mevastatin resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08860</drugbank-id>
      <name>Pitavastatin</name>
      <description>Cholestyramine can cause a decrease in the absorption of Pitavastatin resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01586</drugbank-id>
      <name>Ursodeoxycholic acid</name>
      <description>Cholestyramine can cause a decrease in the absorption of Ursodeoxycholic acid resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB02123</drugbank-id>
      <name>Glycochenodeoxycholic Acid</name>
      <description>Cholestyramine can cause a decrease in the absorption of Glycochenodeoxycholic Acid resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB02659</drugbank-id>
      <name>Cholic Acid</name>
      <description>Cholestyramine can cause a decrease in the absorption of Cholic Acid resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB02691</drugbank-id>
      <name>Glycocholic acid</name>
      <description>Cholestyramine can cause a decrease in the absorption of Glycocholic acid resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB03619</drugbank-id>
      <name>Deoxycholic acid</name>
      <description>Cholestyramine can cause a decrease in the absorption of Deoxycholic acid resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04348</drugbank-id>
      <name>Taurocholic acid</name>
      <description>Cholestyramine can cause a decrease in the absorption of Taurocholic acid resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05990</drugbank-id>
      <name>Obeticholic acid</name>
      <description>Cholestyramine can cause a decrease in the absorption of Obeticholic acid resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06777</drugbank-id>
      <name>Chenodeoxycholic acid</name>
      <description>Cholestyramine can cause a decrease in the absorption of Chenodeoxycholic acid resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08833</drugbank-id>
      <name>Taurochenodeoxycholic acid</name>
      <description>Cholestyramine can cause a decrease in the absorption of Taurochenodeoxycholic acid resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08834</drugbank-id>
      <name>Tauroursodeoxycholic acid</name>
      <description>Cholestyramine can cause a decrease in the absorption of Tauroursodeoxycholic acid resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08857</drugbank-id>
      <name>Bamet-UD2</name>
      <description>Cholestyramine can cause a decrease in the absorption of Bamet-UD2 resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11622</drugbank-id>
      <name>Dehydrocholic acid</name>
      <description>Cholestyramine can cause a decrease in the absorption of Dehydrocholic acid resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11789</drugbank-id>
      <name>Hyodeoxycholic Acid</name>
      <description>Cholestyramine can cause a decrease in the absorption of Hyodeoxycholic Acid resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01609</drugbank-id>
      <name>Deferasirox</name>
      <description>Cholestyramine can cause a decrease in the absorption of Deferasirox resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00973</drugbank-id>
      <name>Ezetimibe</name>
      <description>Cholestyramine can cause a decrease in the absorption of Ezetimibe resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01097</drugbank-id>
      <name>Leflunomide</name>
      <description>Cholestyramine may increase the excretion rate of Leflunomide which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08880</drugbank-id>
      <name>Teriflunomide</name>
      <description>Cholestyramine may increase the excretion rate of Teriflunomide which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08827</drugbank-id>
      <name>Lomitapide</name>
      <description>Cholestyramine can cause a decrease in the absorption of Lomitapide resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00563</drugbank-id>
      <name>Methotrexate</name>
      <description>Cholestyramine may increase the excretion rate of Methotrexate which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00627</drugbank-id>
      <name>Niacin</name>
      <description>Cholestyramine can cause a decrease in the absorption of Niacin resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00571</drugbank-id>
      <name>Propranolol</name>
      <description>Cholestyramine can cause a decrease in the absorption of Propranolol resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00481</drugbank-id>
      <name>Raloxifene</name>
      <description>Cholestyramine can cause a decrease in the absorption of Raloxifene resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00512</drugbank-id>
      <name>Vancomycin</name>
      <description>The therapeutic efficacy of Vancomycin can be decreased when used in combination with Cholestyramine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01095</drugbank-id>
      <name>Fluvastatin</name>
      <description>The serum concentration of Fluvastatin can be decreased when it is combined with Cholestyramine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00412</drugbank-id>
      <name>Rosiglitazone</name>
      <description>The serum concentration of Rosiglitazone can be decreased when it is combined with Cholestyramine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00688</drugbank-id>
      <name>Mycophenolate mofetil</name>
      <description>Cholestyramine may increase the excretion rate of Mycophenolate mofetil which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01024</drugbank-id>
      <name>Mycophenolic acid</name>
      <description>Cholestyramine may increase the excretion rate of Mycophenolic acid which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00511</drugbank-id>
      <name>Acetyldigitoxin</name>
      <description>Cholestyramine can cause a decrease in the absorption of Acetyldigitoxin resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01078</drugbank-id>
      <name>Deslanoside</name>
      <description>Cholestyramine can cause a decrease in the absorption of Deslanoside resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01092</drugbank-id>
      <name>Ouabain</name>
      <description>Cholestyramine can cause a decrease in the absorption of Ouabain resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01396</drugbank-id>
      <name>Digitoxin</name>
      <description>Cholestyramine can cause a decrease in the absorption of Digitoxin resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12843</drugbank-id>
      <name>Oleandrin</name>
      <description>Cholestyramine can cause a decrease in the absorption of Oleandrin resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13240</drugbank-id>
      <name>Cymarin</name>
      <description>Cholestyramine can cause a decrease in the absorption of Cymarin resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13307</drugbank-id>
      <name>Proscillaridin</name>
      <description>Cholestyramine can cause a decrease in the absorption of Proscillaridin resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13467</drugbank-id>
      <name>Lanatoside C</name>
      <description>Cholestyramine can cause a decrease in the absorption of Lanatoside C resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13537</drugbank-id>
      <name>Gitoformate</name>
      <description>Cholestyramine can cause a decrease in the absorption of Gitoformate resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13756</drugbank-id>
      <name>Peruvoside</name>
      <description>Cholestyramine can cause a decrease in the absorption of Peruvoside resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00304</drugbank-id>
      <name>Desogestrel</name>
      <description>Cholestyramine can cause a decrease in the absorption of Desogestrel resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00351</drugbank-id>
      <name>Megestrol acetate</name>
      <description>Cholestyramine can cause a decrease in the absorption of Megestrol acetate resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00367</drugbank-id>
      <name>Levonorgestrel</name>
      <description>Cholestyramine can cause a decrease in the absorption of Levonorgestrel resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00603</drugbank-id>
      <name>Medroxyprogesterone acetate</name>
      <description>Cholestyramine can cause a decrease in the absorption of Medroxyprogesterone acetate resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00717</drugbank-id>
      <name>Norethisterone</name>
      <description>Cholestyramine can cause a decrease in the absorption of Norethisterone resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00783</drugbank-id>
      <name>Estradiol</name>
      <description>Cholestyramine can cause a decrease in the absorption of Estradiol resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00823</drugbank-id>
      <name>Ethynodiol diacetate</name>
      <description>Cholestyramine can cause a decrease in the absorption of Ethynodiol diacetate resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00834</drugbank-id>
      <name>Mifepristone</name>
      <description>Cholestyramine can cause a decrease in the absorption of Mifepristone resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00957</drugbank-id>
      <name>Norgestimate</name>
      <description>Cholestyramine can cause a decrease in the absorption of Norgestimate resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00977</drugbank-id>
      <name>Ethinylestradiol</name>
      <description>Cholestyramine can cause a decrease in the absorption of Ethinylestradiol resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01395</drugbank-id>
      <name>Drospirenone</name>
      <description>Cholestyramine can cause a decrease in the absorption of Drospirenone resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04839</drugbank-id>
      <name>Cyproterone acetate</name>
      <description>Cholestyramine can cause a decrease in the absorption of Cyproterone acetate resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06730</drugbank-id>
      <name>Gestodene</name>
      <description>Cholestyramine can cause a decrease in the absorption of Gestodene resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09123</drugbank-id>
      <name>Dienogest</name>
      <description>Cholestyramine can cause a decrease in the absorption of Dienogest resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09371</drugbank-id>
      <name>Norethynodrel</name>
      <description>Cholestyramine can cause a decrease in the absorption of Norethynodrel resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09389</drugbank-id>
      <name>Norgestrel</name>
      <description>Cholestyramine can cause a decrease in the absorption of Norgestrel resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11619</drugbank-id>
      <name>Gestrinone</name>
      <description>Cholestyramine can cause a decrease in the absorption of Gestrinone resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12474</drugbank-id>
      <name>Lynestrenol</name>
      <description>Cholestyramine can cause a decrease in the absorption of Lynestrenol resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13310</drugbank-id>
      <name>Ormeloxifene</name>
      <description>Cholestyramine can cause a decrease in the absorption of Ormeloxifene resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13528</drugbank-id>
      <name>Chlormadinone</name>
      <description>Cholestyramine can cause a decrease in the absorption of Chlormadinone resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13563</drugbank-id>
      <name>Norgestrienone</name>
      <description>Cholestyramine can cause a decrease in the absorption of Norgestrienone resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13685</drugbank-id>
      <name>Quingestanol</name>
      <description>Cholestyramine can cause a decrease in the absorption of Quingestanol resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13857</drugbank-id>
      <name>Demegestone</name>
      <description>Cholestyramine can cause a decrease in the absorption of Demegestone resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13981</drugbank-id>
      <name>Nomegestrol acetate</name>
      <description>Cholestyramine can cause a decrease in the absorption of Nomegestrol acetate resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14678</drugbank-id>
      <name>Norethindrone enanthate</name>
      <description>Cholestyramine can cause a decrease in the absorption of Norethindrone enanthate resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06789</drugbank-id>
      <name>Hydroxyprogesterone caproate</name>
      <description>The serum concentration of Hydroxyprogesterone caproate can be decreased when it is combined with Cholestyramine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00636</drugbank-id>
      <name>Clofibrate</name>
      <description>Cholestyramine can cause a decrease in the absorption of Clofibrate resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01039</drugbank-id>
      <name>Fenofibrate</name>
      <description>Cholestyramine can cause a decrease in the absorption of Fenofibrate resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01241</drugbank-id>
      <name>Gemfibrozil</name>
      <description>Cholestyramine can cause a decrease in the absorption of Gemfibrozil resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01393</drugbank-id>
      <name>Bezafibrate</name>
      <description>Cholestyramine can cause a decrease in the absorption of Bezafibrate resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08983</drugbank-id>
      <name>Etofibrate</name>
      <description>Cholestyramine can cause a decrease in the absorption of Etofibrate resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09064</drugbank-id>
      <name>Ciprofibrate</name>
      <description>Cholestyramine can cause a decrease in the absorption of Ciprofibrate resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13433</drugbank-id>
      <name>Simfibrate</name>
      <description>Cholestyramine can cause a decrease in the absorption of Simfibrate resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13460</drugbank-id>
      <name>Ronifibrate</name>
      <description>Cholestyramine can cause a decrease in the absorption of Ronifibrate resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13780</drugbank-id>
      <name>Aluminium clofibrate</name>
      <description>Cholestyramine can cause a decrease in the absorption of Aluminium clofibrate resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13849</drugbank-id>
      <name>Clofibride</name>
      <description>Cholestyramine can cause a decrease in the absorption of Clofibride resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13873</drugbank-id>
      <name>Fenofibric acid</name>
      <description>Cholestyramine can cause a decrease in the absorption of Fenofibric acid resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00159</drugbank-id>
      <name>Icosapent</name>
      <description>Cholestyramine can cause a decrease in the absorption of Icosapent resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00244</drugbank-id>
      <name>Mesalazine</name>
      <description>Cholestyramine can cause a decrease in the absorption of Mesalazine resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00328</drugbank-id>
      <name>Indomethacin</name>
      <description>Cholestyramine can cause a decrease in the absorption of Indomethacin resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00461</drugbank-id>
      <name>Nabumetone</name>
      <description>Cholestyramine can cause a decrease in the absorption of Nabumetone resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00465</drugbank-id>
      <name>Ketorolac</name>
      <description>Cholestyramine can cause a decrease in the absorption of Ketorolac resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00469</drugbank-id>
      <name>Tenoxicam</name>
      <description>Cholestyramine can cause a decrease in the absorption of Tenoxicam resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00482</drugbank-id>
      <name>Celecoxib</name>
      <description>Cholestyramine can cause a decrease in the absorption of Celecoxib resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00500</drugbank-id>
      <name>Tolmetin</name>
      <description>Cholestyramine can cause a decrease in the absorption of Tolmetin resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00533</drugbank-id>
      <name>Rofecoxib</name>
      <description>Cholestyramine can cause a decrease in the absorption of Rofecoxib resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00554</drugbank-id>
      <name>Piroxicam</name>
      <description>Cholestyramine can cause a decrease in the absorption of Piroxicam resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00573</drugbank-id>
      <name>Fenoprofen</name>
      <description>Cholestyramine can cause a decrease in the absorption of Fenoprofen resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00580</drugbank-id>
      <name>Valdecoxib</name>
      <description>Cholestyramine can cause a decrease in the absorption of Valdecoxib resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00586</drugbank-id>
      <name>Diclofenac</name>
      <description>Cholestyramine can cause a decrease in the absorption of Diclofenac resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00605</drugbank-id>
      <name>Sulindac</name>
      <description>Cholestyramine can cause a decrease in the absorption of Sulindac resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00712</drugbank-id>
      <name>Flurbiprofen</name>
      <description>Cholestyramine can cause a decrease in the absorption of Flurbiprofen resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00749</drugbank-id>
      <name>Etodolac</name>
      <description>Cholestyramine can cause a decrease in the absorption of Etodolac resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00784</drugbank-id>
      <name>Mefenamic acid</name>
      <description>Cholestyramine can cause a decrease in the absorption of Mefenamic acid resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00795</drugbank-id>
      <name>Sulfasalazine</name>
      <description>Cholestyramine can cause a decrease in the absorption of Sulfasalazine resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00812</drugbank-id>
      <name>Phenylbutazone</name>
      <description>Cholestyramine can cause a decrease in the absorption of Phenylbutazone resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00814</drugbank-id>
      <name>Meloxicam</name>
      <description>Cholestyramine can cause a decrease in the absorption of Meloxicam resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00821</drugbank-id>
      <name>Carprofen</name>
      <description>Cholestyramine can cause a decrease in the absorption of Carprofen resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00861</drugbank-id>
      <name>Diflunisal</name>
      <description>Cholestyramine can cause a decrease in the absorption of Diflunisal resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00936</drugbank-id>
      <name>Salicylic acid</name>
      <description>Cholestyramine can cause a decrease in the absorption of Salicylic acid resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00939</drugbank-id>
      <name>Meclofenamic acid</name>
      <description>Cholestyramine can cause a decrease in the absorption of Meclofenamic acid resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00945</drugbank-id>
      <name>Acetylsalicylic acid</name>
      <description>Cholestyramine can cause a decrease in the absorption of Acetylsalicylic acid resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00991</drugbank-id>
      <name>Oxaprozin</name>
      <description>Cholestyramine can cause a decrease in the absorption of Oxaprozin resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01009</drugbank-id>
      <name>Ketoprofen</name>
      <description>Cholestyramine can cause a decrease in the absorption of Ketoprofen resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01014</drugbank-id>
      <name>Balsalazide</name>
      <description>Cholestyramine can cause a decrease in the absorption of Balsalazide resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01050</drugbank-id>
      <name>Ibuprofen</name>
      <description>Cholestyramine can cause a decrease in the absorption of Ibuprofen resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01250</drugbank-id>
      <name>Olsalazine</name>
      <description>Cholestyramine can cause a decrease in the absorption of Olsalazine resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01283</drugbank-id>
      <name>Lumiracoxib</name>
      <description>Cholestyramine can cause a decrease in the absorption of Lumiracoxib resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01397</drugbank-id>
      <name>Magnesium salicylate</name>
      <description>Cholestyramine can cause a decrease in the absorption of Magnesium salicylate resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01399</drugbank-id>
      <name>Salsalate</name>
      <description>Cholestyramine can cause a decrease in the absorption of Salsalate resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01401</drugbank-id>
      <name>Choline magnesium trisalicylate</name>
      <description>Cholestyramine can cause a decrease in the absorption of Choline magnesium trisalicylate resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01419</drugbank-id>
      <name>Antrafenine</name>
      <description>Cholestyramine can cause a decrease in the absorption of Antrafenine resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01424</drugbank-id>
      <name>Aminophenazone</name>
      <description>Cholestyramine can cause a decrease in the absorption of Aminophenazone resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01435</drugbank-id>
      <name>Antipyrine</name>
      <description>Cholestyramine can cause a decrease in the absorption of Antipyrine resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01600</drugbank-id>
      <name>Tiaprofenic acid</name>
      <description>Cholestyramine can cause a decrease in the absorption of Tiaprofenic acid resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01628</drugbank-id>
      <name>Etoricoxib</name>
      <description>Cholestyramine can cause a decrease in the absorption of Etoricoxib resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB02224</drugbank-id>
      <name>Taxifolin</name>
      <description>Cholestyramine can cause a decrease in the absorption of Taxifolin resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB03585</drugbank-id>
      <name>Oxyphenbutazone</name>
      <description>Cholestyramine can cause a decrease in the absorption of Oxyphenbutazone resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04552</drugbank-id>
      <name>Niflumic acid</name>
      <description>Cholestyramine can cause a decrease in the absorption of Niflumic acid resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04725</drugbank-id>
      <name>Licofelone</name>
      <description>Cholestyramine can cause a decrease in the absorption of Licofelone resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04743</drugbank-id>
      <name>Nimesulide</name>
      <description>Cholestyramine can cause a decrease in the absorption of Nimesulide resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04812</drugbank-id>
      <name>Benoxaprofen</name>
      <description>Cholestyramine can cause a decrease in the absorption of Benoxaprofen resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04817</drugbank-id>
      <name>Metamizole</name>
      <description>Cholestyramine can cause a decrease in the absorption of Metamizole resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04828</drugbank-id>
      <name>Zomepirac</name>
      <description>Cholestyramine can cause a decrease in the absorption of Zomepirac resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05095</drugbank-id>
      <name>Cimicoxib</name>
      <description>Cholestyramine can cause a decrease in the absorption of Cimicoxib resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06725</drugbank-id>
      <name>Lornoxicam</name>
      <description>Cholestyramine can cause a decrease in the absorption of Lornoxicam resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06736</drugbank-id>
      <name>Aceclofenac</name>
      <description>Cholestyramine can cause a decrease in the absorption of Aceclofenac resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06737</drugbank-id>
      <name>Zaltoprofen</name>
      <description>Cholestyramine can cause a decrease in the absorption of Zaltoprofen resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB07402</drugbank-id>
      <name>Azapropazone</name>
      <description>Cholestyramine can cause a decrease in the absorption of Azapropazone resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB07477</drugbank-id>
      <name>Felbinac</name>
      <description>Cholestyramine can cause a decrease in the absorption of Felbinac resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08797</drugbank-id>
      <name>Salicylamide</name>
      <description>Cholestyramine can cause a decrease in the absorption of Salicylamide resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08940</drugbank-id>
      <name>Kebuzone</name>
      <description>Cholestyramine can cause a decrease in the absorption of Kebuzone resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08942</drugbank-id>
      <name>Isoxicam</name>
      <description>Cholestyramine can cause a decrease in the absorption of Isoxicam resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08951</drugbank-id>
      <name>Indoprofen</name>
      <description>Cholestyramine can cause a decrease in the absorption of Indoprofen resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08955</drugbank-id>
      <name>Ibuproxam</name>
      <description>Cholestyramine can cause a decrease in the absorption of Ibuproxam resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08976</drugbank-id>
      <name>Floctafenine</name>
      <description>Cholestyramine can cause a decrease in the absorption of Floctafenine resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08981</drugbank-id>
      <name>Fenbufen</name>
      <description>Cholestyramine can cause a decrease in the absorption of Fenbufen resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08984</drugbank-id>
      <name>Etofenamate</name>
      <description>Cholestyramine can cause a decrease in the absorption of Etofenamate resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08991</drugbank-id>
      <name>Epirizole</name>
      <description>Cholestyramine can cause a decrease in the absorption of Epirizole resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09084</drugbank-id>
      <name>Benzydamine</name>
      <description>Cholestyramine can cause a decrease in the absorption of Benzydamine resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09212</drugbank-id>
      <name>Loxoprofen</name>
      <description>Cholestyramine can cause a decrease in the absorption of Loxoprofen resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09213</drugbank-id>
      <name>Dexibuprofen</name>
      <description>Cholestyramine can cause a decrease in the absorption of Dexibuprofen resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09214</drugbank-id>
      <name>Dexketoprofen</name>
      <description>Cholestyramine can cause a decrease in the absorption of Dexketoprofen resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09215</drugbank-id>
      <name>Droxicam</name>
      <description>Cholestyramine can cause a decrease in the absorption of Droxicam resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09216</drugbank-id>
      <name>Tolfenamic acid</name>
      <description>Cholestyramine can cause a decrease in the absorption of Tolfenamic acid resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09217</drugbank-id>
      <name>Firocoxib</name>
      <description>Cholestyramine can cause a decrease in the absorption of Firocoxib resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09218</drugbank-id>
      <name>Clonixin</name>
      <description>Cholestyramine can cause a decrease in the absorption of Clonixin resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09285</drugbank-id>
      <name>Morniflumate</name>
      <description>Cholestyramine can cause a decrease in the absorption of Morniflumate resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09295</drugbank-id>
      <name>Talniflumate</name>
      <description>Cholestyramine can cause a decrease in the absorption of Talniflumate resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11455</drugbank-id>
      <name>Robenacoxib</name>
      <description>Cholestyramine can cause a decrease in the absorption of Robenacoxib resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11466</drugbank-id>
      <name>Tepoxalin</name>
      <description>Cholestyramine can cause a decrease in the absorption of Tepoxalin resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11518</drugbank-id>
      <name>Flunixin</name>
      <description>Cholestyramine can cause a decrease in the absorption of Flunixin resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12399</drugbank-id>
      <name>Polmacoxib</name>
      <description>Cholestyramine can cause a decrease in the absorption of Polmacoxib resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12445</drugbank-id>
      <name>Nitroaspirin</name>
      <description>Cholestyramine can cause a decrease in the absorption of Nitroaspirin resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12480</drugbank-id>
      <name>Betulinic Acid</name>
      <description>Cholestyramine can cause a decrease in the absorption of Betulinic Acid resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12545</drugbank-id>
      <name>Indobufen</name>
      <description>Cholestyramine can cause a decrease in the absorption of Indobufen resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12610</drugbank-id>
      <name>Ebselen</name>
      <description>Cholestyramine can cause a decrease in the absorption of Ebselen resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13001</drugbank-id>
      <name>Tinoridine</name>
      <description>Cholestyramine can cause a decrease in the absorption of Tinoridine resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13167</drugbank-id>
      <name>Alclofenac</name>
      <description>Cholestyramine can cause a decrease in the absorption of Alclofenac resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13217</drugbank-id>
      <name>Fentiazac</name>
      <description>Cholestyramine can cause a decrease in the absorption of Fentiazac resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13232</drugbank-id>
      <name>Suxibuzone</name>
      <description>Cholestyramine can cause a decrease in the absorption of Suxibuzone resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13286</drugbank-id>
      <name>Bumadizone</name>
      <description>Cholestyramine can cause a decrease in the absorption of Bumadizone resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13314</drugbank-id>
      <name>Alminoprofen</name>
      <description>Cholestyramine can cause a decrease in the absorption of Alminoprofen resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13317</drugbank-id>
      <name>Flunoxaprofen</name>
      <description>Cholestyramine can cause a decrease in the absorption of Flunoxaprofen resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13364</drugbank-id>
      <name>Feprazone</name>
      <description>Cholestyramine can cause a decrease in the absorption of Feprazone resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13371</drugbank-id>
      <name>Difenpiramide</name>
      <description>Cholestyramine can cause a decrease in the absorption of Difenpiramide resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13407</drugbank-id>
      <name>Nifenazone</name>
      <description>Cholestyramine can cause a decrease in the absorption of Nifenazone resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13432</drugbank-id>
      <name>Lonazolac</name>
      <description>Cholestyramine can cause a decrease in the absorption of Lonazolac resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13481</drugbank-id>
      <name>Tenidap</name>
      <description>Cholestyramine can cause a decrease in the absorption of Tenidap resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13501</drugbank-id>
      <name>Bendazac</name>
      <description>Cholestyramine can cause a decrease in the absorption of Bendazac resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13514</drugbank-id>
      <name>Pranoprofen</name>
      <description>Cholestyramine can cause a decrease in the absorption of Pranoprofen resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13524</drugbank-id>
      <name>Propyphenazone</name>
      <description>Cholestyramine can cause a decrease in the absorption of Propyphenazone resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13527</drugbank-id>
      <name>Proglumetacin</name>
      <description>Cholestyramine can cause a decrease in the absorption of Proglumetacin resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13538</drugbank-id>
      <name>Guacetisal</name>
      <description>Cholestyramine can cause a decrease in the absorption of Guacetisal resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13544</drugbank-id>
      <name>Ethenzamide</name>
      <description>Cholestyramine can cause a decrease in the absorption of Ethenzamide resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13612</drugbank-id>
      <name>Carbaspirin calcium</name>
      <description>Cholestyramine can cause a decrease in the absorption of Carbaspirin calcium resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13629</drugbank-id>
      <name>Mofebutazone</name>
      <description>Cholestyramine can cause a decrease in the absorption of Mofebutazone resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13649</drugbank-id>
      <name>Proquazone</name>
      <description>Cholestyramine can cause a decrease in the absorption of Proquazone resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13657</drugbank-id>
      <name>Benorilate</name>
      <description>Cholestyramine can cause a decrease in the absorption of Benorilate resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13722</drugbank-id>
      <name>Pirprofen</name>
      <description>Cholestyramine can cause a decrease in the absorption of Pirprofen resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13783</drugbank-id>
      <name>Acemetacin</name>
      <description>Cholestyramine can cause a decrease in the absorption of Acemetacin resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13860</drugbank-id>
      <name>Imidazole salicylate</name>
      <description>Cholestyramine can cause a decrease in the absorption of Imidazole salicylate resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14059</drugbank-id>
      <name>SC-236</name>
      <description>Cholestyramine can cause a decrease in the absorption of SC-236 resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14060</drugbank-id>
      <name>NS-398</name>
      <description>Cholestyramine can cause a decrease in the absorption of NS-398 resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14938</drugbank-id>
      <name>Flurbiprofen axetil</name>
      <description>Cholestyramine can cause a decrease in the absorption of Flurbiprofen axetil resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00254</drugbank-id>
      <name>Doxycycline</name>
      <description>Cholestyramine can cause a decrease in the absorption of Doxycycline resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00256</drugbank-id>
      <name>Lymecycline</name>
      <description>Cholestyramine can cause a decrease in the absorption of Lymecycline resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00453</drugbank-id>
      <name>Clomocycline</name>
      <description>Cholestyramine can cause a decrease in the absorption of Clomocycline resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00595</drugbank-id>
      <name>Oxytetracycline</name>
      <description>Cholestyramine can cause a decrease in the absorption of Oxytetracycline resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00618</drugbank-id>
      <name>Demeclocycline</name>
      <description>Cholestyramine can cause a decrease in the absorption of Demeclocycline resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00759</drugbank-id>
      <name>Tetracycline</name>
      <description>Cholestyramine can cause a decrease in the absorption of Tetracycline resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00931</drugbank-id>
      <name>Metacycline</name>
      <description>Cholestyramine can cause a decrease in the absorption of Metacycline resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01017</drugbank-id>
      <name>Minocycline</name>
      <description>Cholestyramine can cause a decrease in the absorption of Minocycline resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12035</drugbank-id>
      <name>Sarecycline</name>
      <description>Cholestyramine can cause a decrease in the absorption of Sarecycline resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12455</drugbank-id>
      <name>Omadacycline</name>
      <description>Cholestyramine can cause a decrease in the absorption of Omadacycline resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13092</drugbank-id>
      <name>Meclocycline</name>
      <description>Cholestyramine can cause a decrease in the absorption of Meclocycline resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13264</drugbank-id>
      <name>Penimepicycline</name>
      <description>Cholestyramine can cause a decrease in the absorption of Penimepicycline resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00232</drugbank-id>
      <name>Methyclothiazide</name>
      <description>Cholestyramine can cause a decrease in the absorption of Methyclothiazide resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00310</drugbank-id>
      <name>Chlorthalidone</name>
      <description>Cholestyramine can cause a decrease in the absorption of Chlorthalidone resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00436</drugbank-id>
      <name>Bendroflumethiazide</name>
      <description>Cholestyramine can cause a decrease in the absorption of Bendroflumethiazide resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00524</drugbank-id>
      <name>Metolazone</name>
      <description>Cholestyramine can cause a decrease in the absorption of Metolazone resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00562</drugbank-id>
      <name>Benzthiazide</name>
      <description>Cholestyramine can cause a decrease in the absorption of Benzthiazide resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00774</drugbank-id>
      <name>Hydroflumethiazide</name>
      <description>Cholestyramine can cause a decrease in the absorption of Hydroflumethiazide resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00808</drugbank-id>
      <name>Indapamide</name>
      <description>Cholestyramine can cause a decrease in the absorption of Indapamide resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00880</drugbank-id>
      <name>Chlorothiazide</name>
      <description>Cholestyramine can cause a decrease in the absorption of Chlorothiazide resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00999</drugbank-id>
      <name>Hydrochlorothiazide</name>
      <description>Cholestyramine can cause a decrease in the absorption of Hydrochlorothiazide resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01021</drugbank-id>
      <name>Trichlormethiazide</name>
      <description>Cholestyramine can cause a decrease in the absorption of Trichlormethiazide resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01324</drugbank-id>
      <name>Polythiazide</name>
      <description>Cholestyramine can cause a decrease in the absorption of Polythiazide resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01325</drugbank-id>
      <name>Quinethazone</name>
      <description>Cholestyramine can cause a decrease in the absorption of Quinethazone resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13532</drugbank-id>
      <name>Cyclopenthiazide</name>
      <description>Cholestyramine can cause a decrease in the absorption of Cyclopenthiazide resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13989</drugbank-id>
      <name>Epitizide</name>
      <description>Cholestyramine can cause a decrease in the absorption of Epitizide resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00136</drugbank-id>
      <name>Calcitriol</name>
      <description>The serum concentration of Calcitriol can be decreased when it is combined with Cholestyramine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00146</drugbank-id>
      <name>Calcifediol</name>
      <description>The serum concentration of Calcifediol can be decreased when it is combined with Cholestyramine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00153</drugbank-id>
      <name>Ergocalciferol</name>
      <description>The serum concentration of Ergocalciferol can be decreased when it is combined with Cholestyramine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00169</drugbank-id>
      <name>Cholecalciferol</name>
      <description>The serum concentration of Cholecalciferol can be decreased when it is combined with Cholestyramine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00910</drugbank-id>
      <name>Paricalcitol</name>
      <description>The serum concentration of Paricalcitol can be decreased when it is combined with Cholestyramine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01070</drugbank-id>
      <name>Dihydrotachysterol</name>
      <description>The serum concentration of Dihydrotachysterol can be decreased when it is combined with Cholestyramine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01436</drugbank-id>
      <name>Alfacalcidol</name>
      <description>The serum concentration of Alfacalcidol can be decreased when it is combined with Cholestyramine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04258</drugbank-id>
      <name>Seocalcitol</name>
      <description>The serum concentration of Seocalcitol can be decreased when it is combined with Cholestyramine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04796</drugbank-id>
      <name>Inecalcitol</name>
      <description>The serum concentration of Inecalcitol can be decreased when it is combined with Cholestyramine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04891</drugbank-id>
      <name>Becocalcidiol</name>
      <description>The serum concentration of Becocalcidiol can be decreased when it is combined with Cholestyramine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05295</drugbank-id>
      <name>Eldecalcitol</name>
      <description>The serum concentration of Eldecalcitol can be decreased when it is combined with Cholestyramine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06117</drugbank-id>
      <name>1alpha,24S-Dihydroxyvitamin D2</name>
      <description>The serum concentration of 1alpha,24S-Dihydroxyvitamin D2 can be decreased when it is combined with Cholestyramine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06194</drugbank-id>
      <name>Elocalcitol</name>
      <description>The serum concentration of Elocalcitol can be decreased when it is combined with Cholestyramine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06272</drugbank-id>
      <name>Maxacalcitol</name>
      <description>The serum concentration of Maxacalcitol can be decreased when it is combined with Cholestyramine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06410</drugbank-id>
      <name>Doxercalciferol</name>
      <description>The serum concentration of Doxercalciferol can be decreased when it is combined with Cholestyramine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11094</drugbank-id>
      <name>Vitamin D</name>
      <description>The serum concentration of Vitamin D can be decreased when it is combined with Cholestyramine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13097</drugbank-id>
      <name>1alpha-Hydroxyvitamin D5</name>
      <description>The serum concentration of 1alpha-Hydroxyvitamin D5 can be decreased when it is combined with Cholestyramine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13689</drugbank-id>
      <name>Tacalcitol</name>
      <description>The serum concentration of Tacalcitol can be decreased when it is combined with Cholestyramine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00266</drugbank-id>
      <name>Dicoumarol</name>
      <description>Cholestyramine can cause a decrease in the absorption of Dicoumarol resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00498</drugbank-id>
      <name>Phenindione</name>
      <description>Cholestyramine can cause a decrease in the absorption of Phenindione resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00682</drugbank-id>
      <name>Warfarin</name>
      <description>Cholestyramine can cause a decrease in the absorption of Warfarin resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00946</drugbank-id>
      <name>Phenprocoumon</name>
      <description>Cholestyramine can cause a decrease in the absorption of Phenprocoumon resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01418</drugbank-id>
      <name>Acenocoumarol</name>
      <description>Cholestyramine can cause a decrease in the absorption of Acenocoumarol resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB03410</drugbank-id>
      <name>4-hydroxycoumarin</name>
      <description>Cholestyramine can cause a decrease in the absorption of 4-hydroxycoumarin resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04665</drugbank-id>
      <name>Coumarin</name>
      <description>Cholestyramine can cause a decrease in the absorption of Coumarin resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08496</drugbank-id>
      <name>(R)-warfarin</name>
      <description>Cholestyramine can cause a decrease in the absorption of (R)-warfarin resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08794</drugbank-id>
      <name>Ethyl biscoumacetate</name>
      <description>Cholestyramine can cause a decrease in the absorption of Ethyl biscoumacetate resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13136</drugbank-id>
      <name>Fluindione</name>
      <description>Cholestyramine can cause a decrease in the absorption of Fluindione resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13275</drugbank-id>
      <name>Clorindione</name>
      <description>Cholestyramine can cause a decrease in the absorption of Clorindione resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13347</drugbank-id>
      <name>Diphenadione</name>
      <description>Cholestyramine can cause a decrease in the absorption of Diphenadione resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13451</drugbank-id>
      <name>Tioclomarol</name>
      <description>Cholestyramine can cause a decrease in the absorption of Tioclomarol resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14055</drugbank-id>
      <name>(S)-Warfarin</name>
      <description>Cholestyramine can cause a decrease in the absorption of (S)-Warfarin resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00606</drugbank-id>
      <name>Cyclothiazide</name>
      <description>Cholestyramine can cause a decrease in the absorption of Cyclothiazide resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01119</drugbank-id>
      <name>Diazoxide</name>
      <description>Cholestyramine can cause a decrease in the absorption of Diazoxide resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13430</drugbank-id>
      <name>Mebutizide</name>
      <description>Cholestyramine can cause a decrease in the absorption of Mebutizide resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08896</drugbank-id>
      <name>Regorafenib</name>
      <description>Cholestyramine can cause a decrease in the absorption of Regorafenib resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00203</drugbank-id>
      <name>Sildenafil</name>
      <description>Cholestyramine can cause a decrease in the absorption of Sildenafil resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00263</drugbank-id>
      <name>Sulfisoxazole</name>
      <description>Cholestyramine can cause a decrease in the absorption of Sulfisoxazole resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00311</drugbank-id>
      <name>Ethoxzolamide</name>
      <description>Cholestyramine can cause a decrease in the absorption of Ethoxzolamide resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00359</drugbank-id>
      <name>Sulfadiazine</name>
      <description>Cholestyramine can cause a decrease in the absorption of Sulfadiazine resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00559</drugbank-id>
      <name>Bosentan</name>
      <description>Cholestyramine can cause a decrease in the absorption of Bosentan resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00576</drugbank-id>
      <name>Sulfamethizole</name>
      <description>Cholestyramine can cause a decrease in the absorption of Sulfamethizole resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00664</drugbank-id>
      <name>Sulfametopyrazine</name>
      <description>Cholestyramine can cause a decrease in the absorption of Sulfametopyrazine resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00669</drugbank-id>
      <name>Sumatriptan</name>
      <description>Cholestyramine can cause a decrease in the absorption of Sumatriptan resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00706</drugbank-id>
      <name>Tamsulosin</name>
      <description>Cholestyramine can cause a decrease in the absorption of Tamsulosin resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00819</drugbank-id>
      <name>Acetazolamide</name>
      <description>Cholestyramine can cause a decrease in the absorption of Acetazolamide resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00891</drugbank-id>
      <name>Sulfapyridine</name>
      <description>Cholestyramine can cause a decrease in the absorption of Sulfapyridine resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00909</drugbank-id>
      <name>Zonisamide</name>
      <description>Cholestyramine can cause a decrease in the absorption of Zonisamide resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01015</drugbank-id>
      <name>Sulfamethoxazole</name>
      <description>Cholestyramine can cause a decrease in the absorption of Sulfamethoxazole resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01032</drugbank-id>
      <name>Probenecid</name>
      <description>Cholestyramine can cause a decrease in the absorption of Probenecid resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01144</drugbank-id>
      <name>Diclofenamide</name>
      <description>Cholestyramine can cause a decrease in the absorption of Diclofenamide resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01264</drugbank-id>
      <name>Darunavir</name>
      <description>Cholestyramine can cause a decrease in the absorption of Darunavir resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01298</drugbank-id>
      <name>Sulfacytine</name>
      <description>Cholestyramine can cause a decrease in the absorption of Sulfacytine resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01299</drugbank-id>
      <name>Sulfadoxine</name>
      <description>Cholestyramine can cause a decrease in the absorption of Sulfadoxine resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01382</drugbank-id>
      <name>Glymidine</name>
      <description>Cholestyramine can cause a decrease in the absorption of Glymidine resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01581</drugbank-id>
      <name>Sulfamerazine</name>
      <description>Cholestyramine can cause a decrease in the absorption of Sulfamerazine resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01582</drugbank-id>
      <name>Sulfamethazine</name>
      <description>Cholestyramine can cause a decrease in the absorption of Sulfamethazine resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04707</drugbank-id>
      <name>Hydroxyfasudil</name>
      <description>Cholestyramine can cause a decrease in the absorption of Hydroxyfasudil resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06150</drugbank-id>
      <name>Sulfadimethoxine</name>
      <description>Cholestyramine can cause a decrease in the absorption of Sulfadimethoxine resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06290</drugbank-id>
      <name>Simeprevir</name>
      <description>Cholestyramine can cause a decrease in the absorption of Simeprevir resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06729</drugbank-id>
      <name>Sulfaphenazole</name>
      <description>Cholestyramine can cause a decrease in the absorption of Sulfaphenazole resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06821</drugbank-id>
      <name>Sulfameter</name>
      <description>Cholestyramine can cause a decrease in the absorption of Sulfameter resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB07996</drugbank-id>
      <name>5-(2-methylpiperazine-1-sulfonyl)isoquinoline</name>
      <description>Cholestyramine can cause a decrease in the absorption of 5-(2-methylpiperazine-1-sulfonyl)isoquinoline resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08162</drugbank-id>
      <name>Fasudil</name>
      <description>Cholestyramine can cause a decrease in the absorption of Fasudil resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08798</drugbank-id>
      <name>Sulfamoxole</name>
      <description>Cholestyramine can cause a decrease in the absorption of Sulfamoxole resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08881</drugbank-id>
      <name>Vemurafenib</name>
      <description>Cholestyramine can cause a decrease in the absorption of Vemurafenib resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11389</drugbank-id>
      <name>Clorsulon</name>
      <description>Cholestyramine can cause a decrease in the absorption of Clorsulon resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11461</drugbank-id>
      <name>Sulfachlorpyridazine</name>
      <description>Cholestyramine can cause a decrease in the absorption of Sulfachlorpyridazine resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11462</drugbank-id>
      <name>Sulfaethoxypyridazine</name>
      <description>Cholestyramine can cause a decrease in the absorption of Sulfaethoxypyridazine resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11463</drugbank-id>
      <name>Sulfanitran</name>
      <description>Cholestyramine can cause a decrease in the absorption of Sulfanitran resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11464</drugbank-id>
      <name>Sulfaquinoxaline</name>
      <description>Cholestyramine can cause a decrease in the absorption of Sulfaquinoxaline resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12051</drugbank-id>
      <name>Setrobuvir</name>
      <description>Cholestyramine can cause a decrease in the absorption of Setrobuvir resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12921</drugbank-id>
      <name>Chlorsulfaquinoxaline</name>
      <description>Cholestyramine can cause a decrease in the absorption of Chlorsulfaquinoxaline resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13214</drugbank-id>
      <name>Sulfadicramide</name>
      <description>Cholestyramine can cause a decrease in the absorption of Sulfadicramide resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13248</drugbank-id>
      <name>Phthalylsulfathiazole</name>
      <description>Cholestyramine can cause a decrease in the absorption of Phthalylsulfathiazole resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13283</drugbank-id>
      <name>Sulfaisodimidine</name>
      <description>Cholestyramine can cause a decrease in the absorption of Sulfaisodimidine resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13284</drugbank-id>
      <name>Meticrane</name>
      <description>Cholestyramine can cause a decrease in the absorption of Meticrane resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13320</drugbank-id>
      <name>Sulfaperin</name>
      <description>Cholestyramine can cause a decrease in the absorption of Sulfaperin resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13405</drugbank-id>
      <name>Mefruside</name>
      <description>Cholestyramine can cause a decrease in the absorption of Mefruside resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13485</drugbank-id>
      <name>Sulfametomidine</name>
      <description>Cholestyramine can cause a decrease in the absorption of Sulfametomidine resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13547</drugbank-id>
      <name>Sulfatolamide</name>
      <description>Cholestyramine can cause a decrease in the absorption of Sulfatolamide resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13556</drugbank-id>
      <name>Sulfamazone</name>
      <description>Cholestyramine can cause a decrease in the absorption of Sulfamazone resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13580</drugbank-id>
      <name>Succinylsulfathiazole</name>
      <description>Cholestyramine can cause a decrease in the absorption of Succinylsulfathiazole resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13617</drugbank-id>
      <name>Clorexolone</name>
      <description>Cholestyramine can cause a decrease in the absorption of Clorexolone resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13663</drugbank-id>
      <name>Clofenamide</name>
      <description>Cholestyramine can cause a decrease in the absorption of Clofenamide resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13699</drugbank-id>
      <name>Sulfathiourea</name>
      <description>Cholestyramine can cause a decrease in the absorption of Sulfathiourea resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13708</drugbank-id>
      <name>Fenquizone</name>
      <description>Cholestyramine can cause a decrease in the absorption of Fenquizone resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13726</drugbank-id>
      <name>Sulfaguanidine</name>
      <description>Cholestyramine can cause a decrease in the absorption of Sulfaguanidine resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13773</drugbank-id>
      <name>Sulfamethoxypyridazine</name>
      <description>Cholestyramine can cause a decrease in the absorption of Sulfamethoxypyridazine resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13792</drugbank-id>
      <name>Clopamide</name>
      <description>Cholestyramine can cause a decrease in the absorption of Clopamide resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13803</drugbank-id>
      <name>Xipamide</name>
      <description>Cholestyramine can cause a decrease in the absorption of Xipamide resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14033</drugbank-id>
      <name>Acetyl sulfisoxazole</name>
      <description>Cholestyramine can cause a decrease in the absorption of Acetyl sulfisoxazole resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14708</drugbank-id>
      <name>Tosylchloramide</name>
      <description>Cholestyramine can cause a decrease in the absorption of Tosylchloramide resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00214</drugbank-id>
      <name>Torasemide</name>
      <description>Cholestyramine can cause a decrease in the absorption of Torasemide resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00695</drugbank-id>
      <name>Furosemide</name>
      <description>Cholestyramine can cause a decrease in the absorption of Furosemide resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00887</drugbank-id>
      <name>Bumetanide</name>
      <description>Cholestyramine can cause a decrease in the absorption of Bumetanide resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB02925</drugbank-id>
      <name>Piretanide</name>
      <description>Cholestyramine can cause a decrease in the absorption of Piretanide resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08961</drugbank-id>
      <name>Azosemide</name>
      <description>Cholestyramine can cause a decrease in the absorption of Azosemide resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00252</drugbank-id>
      <name>Phenytoin</name>
      <description>Cholestyramine can cause a decrease in the absorption of Phenytoin resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00390</drugbank-id>
      <name>Digoxin</name>
      <description>The serum concentration of Digoxin can be decreased when it is combined with Cholestyramine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13401</drugbank-id>
      <name>Metildigoxin</name>
      <description>The serum concentration of Metildigoxin can be decreased when it is combined with Cholestyramine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13691</drugbank-id>
      <name>Acetyldigoxin</name>
      <description>The serum concentration of Acetyldigoxin can be decreased when it is combined with Cholestyramine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00024</drugbank-id>
      <name>Thyrotropin alfa</name>
      <description>Cholestyramine can cause a decrease in the absorption of Thyrotropin alfa resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00279</drugbank-id>
      <name>Liothyronine</name>
      <description>Cholestyramine can cause a decrease in the absorption of Liothyronine resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00451</drugbank-id>
      <name>Levothyroxine</name>
      <description>Cholestyramine can cause a decrease in the absorption of Levothyroxine resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01583</drugbank-id>
      <name>Liotrix</name>
      <description>Cholestyramine can cause a decrease in the absorption of Liotrix resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB03604</drugbank-id>
      <name>Tiratricol</name>
      <description>Cholestyramine can cause a decrease in the absorption of Tiratricol resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09100</drugbank-id>
      <name>Thyroid, porcine</name>
      <description>Cholestyramine can cause a decrease in the absorption of Thyroid, porcine resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00788</drugbank-id>
      <name>Naproxen</name>
      <description>Cholestyramine can cause a decrease in the absorption of Naproxen resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00180</drugbank-id>
      <name>Flunisolide</name>
      <description>Cholestyramine may increase the excretion rate of Flunisolide which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00223</drugbank-id>
      <name>Diflorasone</name>
      <description>Cholestyramine may increase the excretion rate of Diflorasone which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00240</drugbank-id>
      <name>Alclometasone</name>
      <description>Cholestyramine may increase the excretion rate of Alclometasone which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00253</drugbank-id>
      <name>Medrysone</name>
      <description>Cholestyramine may increase the excretion rate of Medrysone which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00288</drugbank-id>
      <name>Amcinonide</name>
      <description>Cholestyramine may increase the excretion rate of Amcinonide which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00324</drugbank-id>
      <name>Fluorometholone</name>
      <description>Cholestyramine may increase the excretion rate of Fluorometholone which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00394</drugbank-id>
      <name>Beclomethasone dipropionate</name>
      <description>Cholestyramine may increase the excretion rate of Beclomethasone dipropionate which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00443</drugbank-id>
      <name>Betamethasone</name>
      <description>Cholestyramine may increase the excretion rate of Betamethasone which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00547</drugbank-id>
      <name>Desoximetasone</name>
      <description>Cholestyramine may increase the excretion rate of Desoximetasone which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00588</drugbank-id>
      <name>Fluticasone propionate</name>
      <description>Cholestyramine may increase the excretion rate of Fluticasone propionate which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00591</drugbank-id>
      <name>Fluocinolone acetonide</name>
      <description>Cholestyramine may increase the excretion rate of Fluocinolone acetonide which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00596</drugbank-id>
      <name>Ulobetasol</name>
      <description>Cholestyramine may increase the excretion rate of Ulobetasol which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00620</drugbank-id>
      <name>Triamcinolone</name>
      <description>Cholestyramine may increase the excretion rate of Triamcinolone which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00635</drugbank-id>
      <name>Prednisone</name>
      <description>Cholestyramine may increase the excretion rate of Prednisone which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00663</drugbank-id>
      <name>Flumethasone</name>
      <description>Cholestyramine may increase the excretion rate of Flumethasone which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00687</drugbank-id>
      <name>Fludrocortisone</name>
      <description>Cholestyramine may increase the excretion rate of Fludrocortisone which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00741</drugbank-id>
      <name>Hydrocortisone</name>
      <description>Cholestyramine may increase the excretion rate of Hydrocortisone which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00764</drugbank-id>
      <name>Mometasone</name>
      <description>Cholestyramine may increase the excretion rate of Mometasone which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00838</drugbank-id>
      <name>Clocortolone</name>
      <description>Cholestyramine may increase the excretion rate of Clocortolone which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00846</drugbank-id>
      <name>Flurandrenolide</name>
      <description>Cholestyramine may increase the excretion rate of Flurandrenolide which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00860</drugbank-id>
      <name>Prednisolone</name>
      <description>Cholestyramine may increase the excretion rate of Prednisolone which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14596</drugbank-id>
      <name>Loteprednol etabonate</name>
      <description>Cholestyramine may increase the excretion rate of Loteprednol etabonate which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00896</drugbank-id>
      <name>Rimexolone</name>
      <description>Cholestyramine may increase the excretion rate of Rimexolone which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00959</drugbank-id>
      <name>Methylprednisolone</name>
      <description>Cholestyramine may increase the excretion rate of Methylprednisolone which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01013</drugbank-id>
      <name>Clobetasol propionate</name>
      <description>Cholestyramine may increase the excretion rate of Clobetasol propionate which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01047</drugbank-id>
      <name>Fluocinonide</name>
      <description>Cholestyramine may increase the excretion rate of Fluocinonide which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01108</drugbank-id>
      <name>Trilostane</name>
      <description>Cholestyramine may increase the excretion rate of Trilostane which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01130</drugbank-id>
      <name>Prednicarbate</name>
      <description>Cholestyramine may increase the excretion rate of Prednicarbate which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01222</drugbank-id>
      <name>Budesonide</name>
      <description>Cholestyramine may increase the excretion rate of Budesonide which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01234</drugbank-id>
      <name>Dexamethasone</name>
      <description>Cholestyramine may increase the excretion rate of Dexamethasone which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01260</drugbank-id>
      <name>Desonide</name>
      <description>Cholestyramine may increase the excretion rate of Desonide which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01285</drugbank-id>
      <name>Corticotropin</name>
      <description>Cholestyramine may increase the excretion rate of Corticotropin which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01380</drugbank-id>
      <name>Cortisone acetate</name>
      <description>Cholestyramine may increase the excretion rate of Cortisone acetate which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01384</drugbank-id>
      <name>Paramethasone</name>
      <description>Cholestyramine may increase the excretion rate of Paramethasone which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01410</drugbank-id>
      <name>Ciclesonide</name>
      <description>Cholestyramine may increase the excretion rate of Ciclesonide which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04630</drugbank-id>
      <name>Aldosterone</name>
      <description>Cholestyramine may increase the excretion rate of Aldosterone which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06781</drugbank-id>
      <name>Difluprednate</name>
      <description>Cholestyramine may increase the excretion rate of Difluprednate which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06786</drugbank-id>
      <name>Halcinonide</name>
      <description>Cholestyramine may increase the excretion rate of Halcinonide which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08906</drugbank-id>
      <name>Fluticasone furoate</name>
      <description>Cholestyramine may increase the excretion rate of Fluticasone furoate which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08970</drugbank-id>
      <name>Fluprednidene</name>
      <description>Cholestyramine may increase the excretion rate of Fluprednidene which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08971</drugbank-id>
      <name>Fluocortolone</name>
      <description>Cholestyramine may increase the excretion rate of Fluocortolone which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09091</drugbank-id>
      <name>Tixocortol</name>
      <description>Cholestyramine may increase the excretion rate of Tixocortol which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09095</drugbank-id>
      <name>Difluocortolone</name>
      <description>Cholestyramine may increase the excretion rate of Difluocortolone which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09378</drugbank-id>
      <name>Fluprednisolone</name>
      <description>Cholestyramine may increase the excretion rate of Fluprednisolone which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09383</drugbank-id>
      <name>Meprednisone</name>
      <description>Cholestyramine may increase the excretion rate of Meprednisone which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11487</drugbank-id>
      <name>Dexamethasone isonicotinate</name>
      <description>Cholestyramine may increase the excretion rate of Dexamethasone isonicotinate which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11529</drugbank-id>
      <name>Melengestrol</name>
      <description>Cholestyramine may increase the excretion rate of Melengestrol which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11750</drugbank-id>
      <name>Clobetasol</name>
      <description>Cholestyramine may increase the excretion rate of Clobetasol which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11921</drugbank-id>
      <name>Deflazacort</name>
      <description>Cholestyramine may increase the excretion rate of Deflazacort which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13003</drugbank-id>
      <name>Cortivazol</name>
      <description>Cholestyramine may increase the excretion rate of Cortivazol which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13158</drugbank-id>
      <name>Clobetasone</name>
      <description>Cholestyramine may increase the excretion rate of Clobetasone which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13208</drugbank-id>
      <name>Prednylidene</name>
      <description>Cholestyramine may increase the excretion rate of Prednylidene which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13223</drugbank-id>
      <name>Fluocortin</name>
      <description>Cholestyramine may increase the excretion rate of Fluocortin which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13491</drugbank-id>
      <name>Fluperolone</name>
      <description>Cholestyramine may increase the excretion rate of Fluperolone which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13664</drugbank-id>
      <name>Formocortal</name>
      <description>Cholestyramine may increase the excretion rate of Formocortal which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13728</drugbank-id>
      <name>Halometasone</name>
      <description>Cholestyramine may increase the excretion rate of Halometasone which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13843</drugbank-id>
      <name>Cloprednol</name>
      <description>Cholestyramine may increase the excretion rate of Cloprednol which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13856</drugbank-id>
      <name>Fluclorolone</name>
      <description>Cholestyramine may increase the excretion rate of Fluclorolone which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13867</drugbank-id>
      <name>Fluticasone</name>
      <description>Cholestyramine may increase the excretion rate of Fluticasone which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14512</drugbank-id>
      <name>Mometasone furoate</name>
      <description>Cholestyramine may increase the excretion rate of Mometasone furoate which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14538</drugbank-id>
      <name>Hydrocortisone aceponate</name>
      <description>Cholestyramine may increase the excretion rate of Hydrocortisone aceponate which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14539</drugbank-id>
      <name>Hydrocortisone acetate</name>
      <description>Cholestyramine may increase the excretion rate of Hydrocortisone acetate which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14540</drugbank-id>
      <name>Hydrocortisone butyrate</name>
      <description>Cholestyramine may increase the excretion rate of Hydrocortisone butyrate which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14541</drugbank-id>
      <name>Hydrocortisone cypionate</name>
      <description>Cholestyramine may increase the excretion rate of Hydrocortisone cypionate which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14543</drugbank-id>
      <name>Hydrocortisone probutate</name>
      <description>Cholestyramine may increase the excretion rate of Hydrocortisone probutate which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14544</drugbank-id>
      <name>Hydrocortisone valerate</name>
      <description>Cholestyramine may increase the excretion rate of Hydrocortisone valerate which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14545</drugbank-id>
      <name>Hydrocortisone succinate</name>
      <description>Cholestyramine may increase the excretion rate of Hydrocortisone succinate which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00873</drugbank-id>
      <name>Loteprednol</name>
      <description>Cholestyramine may increase the excretion rate of Loteprednol which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14631</drugbank-id>
      <name>Prednisolone phosphate</name>
      <description>Cholestyramine may increase the excretion rate of Prednisolone phosphate which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14633</drugbank-id>
      <name>Prednisolone hemisuccinate</name>
      <description>Cholestyramine may increase the excretion rate of Prednisolone hemisuccinate which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14634</drugbank-id>
      <name>Fluprednidene acetate</name>
      <description>Cholestyramine may increase the excretion rate of Fluprednidene acetate which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14643</drugbank-id>
      <name>Methylprednisolone aceponate</name>
      <description>Cholestyramine may increase the excretion rate of Methylprednisolone aceponate which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14644</drugbank-id>
      <name>Methylprednisolone hemisuccinate</name>
      <description>Cholestyramine may increase the excretion rate of Methylprednisolone hemisuccinate which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14646</drugbank-id>
      <name>Prednisone acetate</name>
      <description>Cholestyramine may increase the excretion rate of Prednisone acetate which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14652</drugbank-id>
      <name>Clocortolone acetate</name>
      <description>Cholestyramine may increase the excretion rate of Clocortolone acetate which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14659</drugbank-id>
      <name>Melengestrol acetate</name>
      <description>Cholestyramine may increase the excretion rate of Melengestrol acetate which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14669</drugbank-id>
      <name>Betamethasone phosphate</name>
      <description>Cholestyramine may increase the excretion rate of Betamethasone phosphate which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14681</drugbank-id>
      <name>Cortisone</name>
      <description>Cholestyramine may increase the excretion rate of Cortisone which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB15566</drugbank-id>
      <name>Prednisolone acetate</name>
      <description>Cholestyramine may increase the excretion rate of Prednisolone acetate which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00316</drugbank-id>
      <name>Acetaminophen</name>
      <description>Cholestyramine can cause a decrease in the absorption of Acetaminophen resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09288</drugbank-id>
      <name>Propacetamol</name>
      <description>Cholestyramine can cause a decrease in the absorption of Propacetamol resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00794</drugbank-id>
      <name>Primidone</name>
      <description>Cholestyramine can cause a decrease in the absorption of Primidone resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00849</drugbank-id>
      <name>Methylphenobarbital</name>
      <description>Cholestyramine can cause a decrease in the absorption of Methylphenobarbital resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01174</drugbank-id>
      <name>Phenobarbital</name>
      <description>Cholestyramine can cause a decrease in the absorption of Phenobarbital resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00421</drugbank-id>
      <name>Spironolactone</name>
      <description>The risk or severity of hyperkalemia and metabolic acidosis can be increased when Cholestyramine is combined with Spironolactone.</description>
    </drug-interaction>
  </drug-interactions>
  <calculated-properties/>
  <experimental-properties>
    <property>
      <kind>Water Solubility</kind>
      <value>Insoluble</value>
      <source/>
    </property>
  </experimental-properties>
  <external-identifiers>
    <external-identifier>
      <resource>Drugs Product Database (DPD)</resource>
      <identifier>10235</identifier>
    </external-identifier>
    <external-identifier>
      <resource>PubChem Substance</resource>
      <identifier>46506251</identifier>
    </external-identifier>
    <external-identifier>
      <resource>PharmGKB</resource>
      <identifier>PA448974</identifier>
    </external-identifier>
    <external-identifier>
      <resource>Wikipedia</resource>
      <identifier>Cholestyramine</identifier>
    </external-identifier>
    <external-identifier>
      <resource>ChEMBL</resource>
      <identifier>CHEMBL1201625</identifier>
    </external-identifier>
  </external-identifiers>
  <external-links>
    <external-link>
      <resource>RxList</resource>
      <url>http://www.rxlist.com/cgi/generic/cholestyramine.htm</url>
    </external-link>
    <external-link>
      <resource>Drugs.com</resource>
      <url>http://www.drugs.com/cdi/cholestyramine-powder.html</url>
    </external-link>
  </external-links>
  <pathways/>
  <reactions/>
  <snp-effects/>
  <snp-adverse-drug-reactions/>
  <targets>
    <target position="1">
      <id>BE0004809</id>
      <name>Bile acids</name>
      <organism>Humans</organism>
      <actions>
        <action>binder</action>
      </actions>
      <references>
        <articles>
          <article>
            <ref-id>A17011</ref-id>
            <pubmed-id>9659597</pubmed-id>
            <citation>Nichifor M, Cristea D, Mocanu G, Carpov A: Aminated polysaccharides as bile acid sorbents: in vitro study. J Biomater Sci Polym Ed. 1998;9(6):519-34.</citation>
          </article>
          <article>
            <ref-id>A17012</ref-id>
            <pubmed-id>9002463</pubmed-id>
            <citation>Benson GM, Alston DR, Hickey DM, Jaxa-Chamiec AA, Whittaker CM, Haynes C, Glen A, Blanchard S, Cresswell SR, Suckling KE: SK&amp;F 97426-A: a novel bile acid sequestrant with higher affinities and slower dissociation rates for bile acids in vitro than cholestyramine. J Pharm Sci. 1997 Jan;86(1):76-81.</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
        <attachments/>
      </references>
      <known-action>yes</known-action>
    </target>
  </targets>
  <enzymes/>
  <carriers/>
  <transporters/>
</drug>